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IT has been reported that cortisone increases metastatic spread in mice bearing
the following transplanted and induced tumors: mammary adenocarcinomas
K7 (Agosin et al., 1952), DBA (Baserga and Shubik, 1954), K9, Sa and Sb (unpub-
lished work of Vergara et al.), bladder carcinoma T150 (Baserga and Shubik,
1955), methylcholanthrene-induced squamous cell carcinoma and methylcholan-
threne-induced sarcoma (Baserga and Shubik, 1954).
Thephenomenon,however,isnotgeneralandthefollowingmousetransplantable
tumors do not seem to be affected by treatment with cortisone: mammary
adenocarcinomas Acc. 635 (Sparks et al., 1955), Eo771 and C3HBA (unpublished
observations of Gasic and Gasic), Sarcoma 1 (Kaliss, Borges, and Day, 1954) and
Sarcoma 180, carcinogen-induced fibrosarcoma GL46, and DBA melanoma
(unpublished work of Gasic and Gasic).
The opposite phenomenon has even been reported, namely that cortisone
decreases the metastatic spread of a mammary adenocarcinoma which originated
in a Z mouse (Martinez and Bittner, 1955).
In those cases in which cortisone enhances the spread, it has been shown that
at least one of the actions of the hormone is concerned with the implantation
and growth of the tumor emboli, following their release into the circulation
(Pomeroy, 1954; Baserga and Shubik, 1955; Goldie et al., 1955; unpublished
results of H. Maturana and of J. Vergara et al.). However, no attempt has been
made to investigate, in a direct way, whether cortisone may also influence the
release of tumor emboli from the primary tumor. To study this possibility, the
presence of stray neoplastic cells has been compared in cortisone-treated and
untreated tumor-bearing animals.
MATERIALS AND METHODS
Three transplantable mouse tumors were used: the bladder carcinoma T150
(Baserga and Saffiotti, 1955) which can grow progressively in C57BL, C57BR,
DBA/1, DBA/2 and C3H, the carcinogen-induced fibrosarcoma GL46 (Baserga
and Baum, 1955) and Sarcoma 180 (Greene and Murphy, 1954). They were inocu-
lated subcutaneously as cellular suspensions, into the left flanks of homologous
hosts, each receiving 1 or 1 ofa standard dose, contained in 0.20 ml. ofa suspension
prepared with one part ofthe tumor, finely minced with scissors, and two parts of
saline.
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At variable intervals after transplantation, both cortisone-treated and
untreated animals were bled from the right heart, under ether anaesthesia. To
avoid puncturing the lung with the needle, the bleeding was made with the thorax
opened. 050 or 0.75 ml. of blood was obtained and inoculated immediately into
the peritoneal cavity of susceptible hosts. These recipients were allowed to live
until natural death or were killed at variable intervals after blood inoculation.
Both donors and the recipients were autopsied. In the former the weight of the
primary tumor was determined and the number oflung metastases were counted.
In the latter the presence of peritoneal growth and hemorrhagic ascites was
ascertained.
Cortisone was given at variable periods after tumor inoculation, each animal
receiving six or ten daily injections of 0.75 mg. of cortisone acetate (" Cortone ",
Merck and Co.) intraperitoneally. To avoid infections in this group, the cortisone
suspension was mixed with streptomycin and oxytetracycline, dissolved in isotonic
aqueous KC1. Each mouse received 1 mg. ofeach antibiotic. The same amount of
these substances, but without cortisone, was given to the control group.
EXPERIMENTAL
(a) Carcinoma T150 into C57BL/6 mice
One-eighth of the standard dose was transplanted into 2-month-old male
and femnale mice in Experiments 1 and 2, and into 3-5-month-old male and female
mice in Experiment 3. The first experiment consisted only of untreated mice
whereas in Experiments 2 and 3 there were both cortisone-treated and untreated
animals. These latter groups received ten injections of cortisone, which were
started 10 and 14 days after tumor implantation, respectively. The bleeding was
performed on the fifteenth day after transplantation in Experiment 1, on the
twentieth day in Experiment 2, and on the twenty-sixth day in Experiment 3.
The blood obtained was inoculated into 1 month-old C57BL/6 mice, generally
of the same sex as the donors.
The results (Table I) are as follows:
TABLE I.-Number of Recipients with Peritoneal Growth. Primary Tumor
and Metastases in the Blood Donors
Blood donors Recipients
Mice with
Average Mice with Av. number Time of peritoneal Av. sv.
primary metastases metastases bleeding growth after
Exper. Cortisone- tumor r----- per (days after - inocul.
no. treated wt. (g) Rate %O mouse inoculation) Rate % (days)
1* No . 2.1 15/23 65 4-0 15 . 16/22 72 29
2* . No . 2-1 15/19 79 7.0 20 . 17/19 89 26
Yes . 1.8 18/21 86 13-1 20 17/21 80 25
3* . No . 2-8 34/37 92 11.0 26 . 27/33 82 24
Yes . 2-6 34/35 98 32.0 26 . 23/31 74 22
* Carcinoma T150.
Experiment 1.-(1) Donors: Lung metastases were observed in 15 of the 23
animals (65 per cent), the average number per mouse being 4. (2) Recipients:
16 out of 22 mice had peritoneal growth and hemorrhagic ascites (72 per cent)
and lived 29 days following inoculation.
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Experiment 2.-(2) Donors: Lung metastases were present in 15 of the 19
controls (79 per cent) and in 18 of the 21 cortisone-treated mice (86 per cent).
The number of metastases per mouse was 7.1 and 13.1 respectively and corre-
sponding figures for the primary tumor weights were 2.1 and 1.8 g. (2) Recipients:
The survival of mice receiving blood from untreated donors was 26 days as
compared with 25 days in the case of recipients of blood from treated donors.
Malignant peritoneal growth with hemorrhagic ascites was observed in 17 of the
19 animals in the first group (89 per cent) and in 17 of the 21 in the second group
(80 per cent).
Experiment 3.-(1) Donors: Thirty-four controls out of 37 (92 per cent) and
34 cortisone-treated mice out of 35 (98 per cent) showed lung metastases, with an
average number of 11 and 32 respectively. The average weight of the primary
tumor was 2.8 g. in the first and 2.6 g. in the second group. (2) Recipients:
peritoneal growth with hemorrhagic ascites was seen in 27 of 33 animals (82 per
cent) that received blood from untreated donors and in 23 of 31 mice (74 per cent)
inoculated with blood from the treated donors. The survival time was respectively
24 and 22 days.
(b) Fibrosarcoma GL46 into DBA/2 mice
One-half the standard dose was inoculated into 2-month-old mice. They were
only females inExperiment 4 and ofboth sexes in Experiment 5. Halfthe animals
of Experiment 5 received ten injections of cortisone from the fifth day onward.
Animals of the second group (Experiment 5) received no additional treatment.
Female mice, 1 month old, acted as recipients ofthe blood drawn from Experiment
4 and Experiment 5, 15 and 16 days after tumor implantation. These mice were
in turn sacrificed 60 and 53 days after blood inoculation.
The following results are recorded in Table II:
TABLE II.-Number of Recipients with Peritoneal Growth. Primary Tuwmor
and Metastases in the Blood Donors
Blood donors Recipients
A ^ , 5
Average Time of Mice with Av. Sv.
primary Mice with bleeding peritoneal after
Exper. Cortisone tumor metastases (day after growths inoculation
no. treated wt. (g.) (Rate) inoculation) (rate) (days)
4* No . 1- 7 0/21 15 0/'21 60
5* . No . 2-6 0/15 16 . 015 53
Yes . 1- 8 0/14 16 . 0/14 53
6t . No . 0.9 0/23 10 0/'23 58
Yes . 0-9 0/24 10 . 0/22 58
* GL46-a transplantable fibrosarcoma.
t Sarcoma 180.
Experiment 4.-The average weight of the primary tumor in the donors was
1.7 g. No metastases were observed in 21 animals, nor were malignant peritoneal
growths present in the 21 recipients of the blood from the untreated donors.
Experiment 5.-No metastases were evident in the 15 untreated or 14 cortisone-
treated donors, nor was there peritoneal growth in any of the mice that received
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blood from these donors. Theirprimary tumorweights were 2.6 g. in the untreated
and 1-8 g. in the treated mice.
(c) Sarcoma 180 into Swiss mice
Two-month-old female Swiss mice received 1 ofthe standard dose ofthe tumor.
Six injections of cortisone were given to half of them, starting 5 days after trans-
plantation. Ten days after tumor implantation these animals were killed and
0.5 ml. samples of their blood were inoculated into Swiss female mice, 1 month
old. These recipients were killed 58 days later.
Results (Experiment 6 in Table II).-The weight of the primary tumor in
both groups of donors averaged 0.9 g. No metastases were seen in any of these
animals; none of the 23 recipients of blood from the untreated donors nor of the
22 inoculated with blood from the cortisone-treated donors had peritoneal growths.
DISCUSSION
To study the emboli release from the primary tumor, the ideal method would
be to draw the venous blood from the tumor itself and to collect it for as long
a period as possible. As this is not possible in mice, it was decided to collect
venous blood from the right heart, in an effort to get the maximum amount of
circulating fluid. However, the amount of blood coming from the tumor must be
small and presumably contained few malignant emboli.
The fact that recipients of blood from tumor-bearing donors show peritoneal
growth, indicates, without any reasonable doubt, that tumor cells were present
in the circulating blood. Though the absence of malignancy in the recipients
does not exclude the presence of a few circulating tumor cells in the donors*,
from a practical point of view, such lack of tumor growth will be assumed to
indicate absence of circulating emboli in the donors. With this reservation,
certain comments can be made about the experimental results reported.
In untreated tumor-bearing mice there seems to be a correlation between the
presence of circulating emboli and the spontaneous capacity of the neoplasm
for producing metastases. When tumor cells were detected in the circulation,
secondary tumors were also detected in the lung. On the contrary, when the
emboli were absent, no metastases were noted. Nevertheless, these results do not
eliminate the possibility that lack of metastases may be associated with the
presence of tumor emboli in the circulation in amounts which might be revealed
by more subtle methods.
Cortisone induced apositive metastatic effect onlywhen the host was inoculated
with a malignantgrowthwhich, like T150, hasthespontaneous capacityfordeliver-
ing tumor emboli into the circulation. No such result was encountered with
GL46 and Sarcoma 180, which under natural conditions do not release emboli
into the circulation, at least during the survival time of the study. However,
by using a bio-assay technique, Goldie et al. (1955) were able to detect the existence
of tumor cells in the liver, lung and brain in untreated CFW mice, 6 days after
transplantation of Sarcoma 180, but in this case the tumor was inoculated into
the peritoneal cavity of the donors.
* It is known that the peritoneal take of a neoplasm may require in certain cases more than 50 cells (Sugiura, 1953) or 1000 (unpublished work of Barahona et al.).
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It appears from these experiments that cortisone has no effect on circulating
tumor emboli. When these are naturally absent, as in Sarcoma 180 and GL46,
cortisone does not make them appear. When, as with T150 circulating emboli
occur natufally, cortisone does not appear to modify their number.
In summary, it may be said that no evidence was found in this experimental
work supporting participation of cortisone in the phenomenon of the emboli
release from theprimary tumor. This conclusionis also supported by other experi-
ments of the authors (unpublished) in which the spontaneous release of emboli
from tumorT150isnot correlatedwithanincreaseoftheadrenalactivity, measured
by the blood eosinophilia and by the thymus and adrenal weights, before and
after metastases have appeared.
SUMMARY
The occurrence of circulating neoplastic cells was studied in cortisone-treated
and in untreated tumor-bearing mice which received isografts of three different
neoplasms. It was found that the hormonal treatment did not modify the pre-
existing number of circulating emboli. In addition, it was observed that the
enhancing effect of cortisone on secondary tumors was only present in animals
inoculated with a tumor which has the natural capacity of delivering malignant
emboli into the circulation.
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